Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. reports developments for a medical technology company focused on physical rehabilitation and recovery. Its product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, with use in clinical settings and in home or community rehabilitation.
Company news covers financial results, access initiatives for the FDA-cleared ReWalk Personal Exoskeleton, collaborations with rehabilitation providers, and regulatory or clinical disclosures tied to rehabilitation technologies. Other recurring updates address Nasdaq listing compliance, shareholder voting matters, governance changes, material agreements, acquisitions, and capital-structure actions involving ordinary shares and warrants.
Lifeward (Nasdaq: LFWD) appointed Dr. Keith D. Rose as Chief Medical Officer, effective May 19, 2026, to lead its global medical strategy.
Dr. Rose brings 30 years of rehabilitation and neuroscience experience and will support expansion of Lifeward’s neurorehabilitation portfolio and newly acquired biomedical assets.
Lifeward (Nasdaq:LFWD) reported Q1 2026 revenue of $3.9 million, down 22% year-over-year, with gross margin of 34.2%. ReWalk personal exoskeleton sales rose 11% to $1.6 million, while AlterG revenue fell 38% to $2.1 million.
The company closed its Oratech strategic transaction, adding $6.5 million in cash and the Protein Oral Delivery platform, and received $10 million in financing. Operating cash burn fell 33% year-over-year, and unrestricted cash increased to $11.4 million. Lifeward will delay filing its Q1 2026 Form 10-Q to finalize accounting for the March 2026 transaction.
Lifeward (Nasdaq: LFWD) will report first quarter 2026 financial results before U.S. markets open on Friday, May 15, 2026. Management will host a conference call and live webcast at 8:30 a.m. EDT to discuss the results.
Investors can access the call via U.S. toll-free, international, and country-specific numbers or via webcast on the Lifeward investor relations website, where an archived replay will also be available.
Lifeward (Nasdaq: LFWD) presented decade-plus real‑world safety data for the ReWalk Personal Exoskeleton at ASIA 2026. A global 2013–2025 dataset shows a 3% lifetime lower‑extremity fracture prevalence, falling to 0.3% in 2020–2025. A Germany registry (2018–2025) reports zero fractures among 97 tracked users since 2018.
The analysis links most fracture events to earlier years (87% in 2014–2019) and highlights diverse patient profiles, device iterations, and increased training and device changes as likely contributors to improved safety.
Lifeward (Nasdaq: LFWD) closed its strategic partnership with Oramed on March 25, 2026, acquiring Oramed's clinical-stage POD™ protein oral delivery technology and positioning the company as a diversified biomedical innovator with an asserted clear path to profitability.
Lifeward gained access to up to $47 million of capital from Oramed and certain investors and accessed $10 million on March 25, 2026; the company also implemented changes to its board of directors.
Lifeward (Nasdaq: LFWD) reported Q4 and full‑year 2025 results and announced a shareholder‑approved strategic transaction with Oramed that transfers the POD™ oral protein delivery platform to Lifeward and could provide up to $47 million in funding.
2025 revenue was $22.0M, net loss $19.9M, GAAP operating expenses fell 25%, and unrestricted cash was $2.2M. Lifeward also agreed to acquire an upper‑body exoskeleton and secured expanded U.S. Medicare Advantage reimbursement for ReWalk.
Lifeward (Nasdaq: LFWD) received shareholder approval to close a strategic partnership with Oramed (Nasdaq: ORMP) that integrates Oramed’s POD™ oral protein delivery platform into Lifeward while Oramed acquires a significant equity stake.
The structure provides Lifeward potential access to up to $47 million, keeps Oramed responsible for POD™ clinical funding, and aims to combine near‑term MedTech profitability with long‑term biotech upside.
Lifeward (Nasdaq: LFWD) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, a condition satisfied on March 9, 2026. The Nasdaq Listing Qualifications Staff considers the prior bid price deficiency closed and Lifeward ordinary shares will continue trading on The Nasdaq Capital Market.
Lifeward (Nasdaq: LFWD) will report fourth quarter and full year 2025 financial results before markets open on March 18, 2026. A live conference call and webcast with CEO Mark Grant and CFO Almog Adar begins at 8:30 a.m. EST. An archived webcast will be available on the Investors Events Calendar.
Lifeward (Nasdaq: LFWD) announced a collaboration with Shirley Ryan AbilityLab to launch dedicated clinic days in Q2 2026 to accelerate evaluation and access to the ReWalk Personal Exoskeleton for people with spinal cord injury (SCI).
Shirley Ryan AbilityLab will lead clinical evaluation, training and patient support, while Lifeward provides ReWalk, an FDA-cleared wearable robotic system enabling standing, walking, and navigation of stairs and curbs.